TSO3 RESUBMITS DOCUMENTS TO PROCEED WITH US REGULATORY CLEARANCEFriday, April 20, 2012
TSO3Resubmits documents to proceed with US regulatory clearance
Quebec City, April 20, 2012 – TSO3 Inc. (“TSO3”) (TSX: TOS), an innovator in sterilization technology for medical devices in healthcare settings, announced today that it is resubmitting documentation to the United States (U.S.) regulatory authorities for the STERIZONE® 125L+ Sterilizer (3M™ Optreoz™ 125-Z) and associated accessories. This filing is aimed at obtaining clearance for the new generation sterilizer for commercialization in the United States.
“Resubmitting this updated filing has been a top priority for TSO3 over the past six weeks”, commented R.M. (Ric) Rumble, CEO of TSO3. “Today’s re-submittal is a follow-up to our original filing of June 30, 2011, and provides the Agency with additional data addressing specific requests. We have had additional consultant input on this re-submittal and we are optimistic that this will lead to a positive outcome”, added Mr. Rumble.
The STERIZONE® 125L+ Sterilizer is covered by a global commercial agreement between TSO3 and 3M under the brand name 3M™ Optreoz™ 125Z. The product has received regulatory clearance for sale in Canada, the European Union and selected countries of Latin America and Asia Pacific.
TSO3, founded in Québec City in 1998, specializes in the research and development of innovative, high-performance medical instrument sterilization technology with high commercial potential. TSO3 designs products for sterile processing areas in the hospital environment and offers an advantageous replacement solution to other low temperature sterilization processes currently used in hospitals.
For more information about TSO3, visit the Company's Web site at www.tso3.com
The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties.
The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it.
Source: TSO3 Inc.
Director – Investor and Business Relations
(418) 651-0003, Ext. 237